Plasmoquin Should NOT Be Used for Psoriatic Arthritis
Plasmoquin (pamaquine) is not recommended for the treatment of psoriatic arthritis and is not included in any current treatment guidelines for this condition. The drug you may be thinking of is Plaquenil (hydroxychloroquine), which is also generally avoided in psoriatic arthritis due to significant safety concerns.
Critical Distinction: Plasmoquin vs. Plaquenil
- Plasmoquin (pamaquine): An 8-aminoquinoline antimalarial used for radical cure of malaria, NOT for rheumatologic conditions
- Plaquenil (hydroxychloroquine): A 4-aminoquinoline that has limited and controversial use in inflammatory arthritis
Current Evidence-Based Treatment Options
According to the 2024 EULAR guidelines 1, the approved pharmacological treatments for psoriatic arthritis include:
First-Line Options:
- Conventional synthetic DMARDs: Methotrexate, sulfasalazine, leflunomide
- NSAIDs and local corticosteroid injections for symptomatic management
Advanced Therapies:
- TNF inhibitors: Adalimumab, certolizumab, etanercept, infliximab, golimumab
- IL-17 inhibitors: Ixekizumab, secukinumab, bimekizumab
- IL-23 inhibitors: Guselkumab, risankizumab
- IL-12/23 inhibitor: Ustekinumab
- JAK inhibitors: Tofacitinib, upadacitinib
- PDE4 inhibitor: Apremilast
Why Antimalarials Are Problematic in Psoriatic Arthritis
High Risk of Severe Cutaneous Reactions:
The FDA drug label for Plaquenil 2 explicitly warns that it "may precipitate attacks of psoriasis." Historical evidence demonstrates:
- Exfoliative erythroderma reported within 11 days of hydroxychloroquine initiation 3
- A 1985 case series concluded that antimalarials are "associated with a high incidence of severe cutaneous adverse reactions" and "should not be used in psoriatic patients if other less toxic, effective therapies are available" 3
Contradictory Older Data:
While some older studies from the 1990s suggested chloroquine might be effective 4, 5, these findings have not been validated in modern trials, and the drugs are notably absent from all current international guidelines 1, 6, 7, 8, 9, 10.
Clinical Pitfalls to Avoid
- Do not confuse Plasmoquin with Plaquenil - they are different drugs with different indications
- Do not use hydroxychloroquine/chloroquine in psoriatic arthritis - the risk of precipitating severe psoriatic flares outweighs any potential benefit
- The 6-8% exacerbation rate reported in older studies 4, 5 likely underestimates the true risk, as severe cases like erythroderma were documented 3
Recommended Approach
For peripheral arthritis: Start with methotrexate or another conventional synthetic DMARD, escalating to biologics (TNF, IL-17, or IL-23 inhibitors) if inadequate response 1
For predominant skin disease with arthritis: Consider IL-17 or IL-23 inhibitors as they effectively target both domains 6
For axial involvement: Biologics (particularly TNF or IL-17 inhibitors) are preferred over conventional DMARDs 8
The evidence is clear: antimalarials have no role in modern psoriatic arthritis management given the availability of safer, more effective alternatives with proven efficacy in reducing joint damage and improving quality of life 1, 6.